Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Officials offer vaccine reassurance; WHO advises against travel bans

11/30/2021 | 06:42pm EST
Arrivals at the international terminal at Sydney Airport as countries react to the new coronavirus Omicron variant

FRANKFURT/BERLIN (Reuters) - The World Health Organization warned countries on Tuesday not to impose blanket travel bans over the new Omicron coronavirus variant as governments and scientists try to determine how much protection current vaccines would offer against the strain.

Financial markets fell sharply after the head of drugmaker Moderna said existing COVID-19 vaccines would be less effective against the Omicron variant. MSCI's gauge of stocks across the globe shed 1.39% a day after broad declines in Europe and Asia.[MKTS/GLOB]

BioNTech's chief executive struck a cautiously positive note, saying the vaccine it makes in a partnership with Pfizer would likely offer strong protection against severe disease from Omicron, which was first reported in southern Africa a week ago.

The questions over vaccine effectiveness came as cases of the new variant spread, with the first reported case in Latin America emerging in Brazil. The country's health regulator, Anvisa, said a traveller arriving in Sao Paulo from South Africa and his wife were both apparently infected.

Canada will extend its ban on travellers from southern Africa to also cover those from Nigeria, Malawi and Egypt, health officials said on Tuesday, for a total of 10 countries. Canada will require people arriving by air from all nations except the United States to take a COVID-19 test, Health Minister Jean-Yves Duclos said.

The U.S. Centers for Disease Control and Prevention (CDC) on Tuesday advised Americans against travel to Niger, Papua New Guinea, Poland, and Trinidad and Tobago. The CDC now lists about 80 destinations at its "Level 4: Very High" classification after the White House announced new travel restrictions in response to Omicron.

The World Health Organization (WHO) asked countries to apply "an evidence-informed and risk-based approach" with any travel measures, including possible screening or quarantine of international passengers. Blanket travel bans would not stop the spread of Omicron, it said.

The WHO issued a statement advising a postponement of travel for those who are unwell or at higher risk of developing severe COVID-19, including those 60 years or older who are not vaccinated.

WHO Director-General Tedros Adhanom Ghebreyesus said he understood the concerns about Omicron.

But he added: "I am equally concerned that several member states are introducing blunt, blanket measures that are not evidence-based or effective on their own, and which will only worsen inequities."

VACCINE QUESTIONS

The European Medicines Agency's (EMA) executive director, Emer Cooke, told the European Parliament that existing vaccines will continue to provide protection.

Andrea Ammon, chair of the European Centre for Disease Prevention and Control (ECDC), said the cases of Omicron so far confirmed in 10 European Union countries were mild or without symptoms, although in younger age groups.

News of Omicron's emergence wiped roughly $2 trillion off global stocks on Friday, after it was first identified in southern Africa and announced on Nov. 25.

U.S. markets on Tuesday reacted mainly to Federal Reserve Chair Jerome Powell's comments signalling a possible speed-up in the taper of the Fed's asset purchase program, but concerns over Omicron's impact added to jitters, market analysts said. The Dow Jones Industrial Average closed down 652.22 points, or 1.86%, to 34,483.72, and the S&P 500 lost 88.27 points, or 1.90%, to 4,567.

"There is no world, I think, where (the effectiveness) is the same level...we had with Delta," Moderna's CEO, Stephane Bancel, told the Financial.

"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to ... are like, 'this is not going to be good'."

Reuters could not reach Moderna for comment.

The University of Oxford said there was no evidence that current vaccines would not prevent severe disease from Omicron, but that it was ready to rapidly update its shot, developed with AstraZeneca, if necessary.


Graphic: OMICRON VARIANT MAP:

The administration of U.S. President Joe Biden suffered two more legal setbacks on vaccine policy on Tuesday. A federal judge blocked a vaccination rule for healthcare workers and applied the ruling nationwide where the mandate was still in effect.

Another federal judge blocked the U.S government from enforcing a vaccination mandate on government contractors in three states.

LAB TESTS

Regeneron Pharmaceuticals said its COVID-19 antibody cocktail and other similar antiviral treatments could be less effective against the latest variant.

EMA's Cooke said "cross neutralisation," a lab test for whether the approved vaccines are effective against Omicron, would take about two weeks. If there was a need to change COVID-19 vaccines, new ones could be approved within three or four months, she said.

"Vaccination will likely still keep you out of the hospital," said John Wherry, director of the Penn Institute for Immunology in Philadelphia.

Moderna and fellow drugmakers BioNTech and Johnson & Johnson are already working on vaccines that specifically target Omicron. Moderna has also been testing a higher dose of its existing booster.

BioNTech Chief Executive Ugur Sahin told Reuters that BioNTech and Pfizer's vaccine was likely to offer strong protection against severe disease from the new variant.

Sahin said he expects lab tests to show some loss of protection against mild and moderate disease due to Omicron but the extent of that loss was hard to predict.

BORDER CONTROLS

Border closures have already cast a shadow over economic recovery, with parts of Europe now seeing a fourth wave of infections as winter sets in.

Japan confirmed its first case of the new variant on Tuesday, in a traveller from Namibia. Australia found that a person with Omicron had visited a busy shopping centre in Sydney while probably infectious.


Graphic: The spread of COVID-19 variants of concern:

Australia on Monday delayed the reopening of its international borders by two weeks, less than 36 hours before foreign students and skilled migrants were to be allowed back.

Britain and the United States have both pushed their booster programmes in response to the new variant. London said international arrivals would have to self-isolate until they get a negative result in a PCR test.

Greece said vaccination would be compulsory for those over 60, the group seen as most vulnerable to COVID-19.

The picture of COVID cases was mixed.

In Germany, a current hotspot of the previous significant variant, Delta, the seven-day average infection rate fell slightly for the first time in three weeks after new restrictions to slow transmission.

France registered its highest daily infection tally since April. And the Dutch health authority said Omicron was already spreading in the Netherlands, where intensive care beds are running out and measures including restrictions on hospitality have yet to take effect.

The curbs on travellers from southern Africa have highlighted the inequality of vaccine distribution, which may have given the virus more opportunities to mutate.

(Reporting by Reuters bureaux worldwide; Writing by Himani Sarkar, Kevin Liffey and Grant McCool; Editing by Angus MacSwan, Mark Heinrich and Leslie Adler)

By Ludwig Burger and Emma Thomasson


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 2.65% 8770 Delayed Quote.-1.54%
REGENERON PHARMACEUTICALS -0.14% 615.24 Delayed Quote.-2.58%
All news about ASTRAZENECA PLC
07:00aCORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with H..
BU
04:37aEnhertu granted Priority Review in the US for patients with HER2-positive metastatic br..
AQ
03:01aCline Scientific extends collaboration agreement with AstraZeneca
AQ
02:40aAstraZeneca's Enhertu Granted Priority Review by US Regulator
DJ
02:31aJens Lindberg takes office as CEO of Medivir on January 24
AQ
02:23aAstraZeneca-Daiichi Sankyo's Breast Cancer Drug Accepted For Priority Review in US
MT
02:06aProsecution Takes Over Case of 8 Medics Pinned for Misusing Covid-19 Vaccines
AQ
01:09aIsrael Reopens Borders To Entry By Foreign Nationals
AQ
01/14EMA lists rare spinal condition as side effect of AstraZeneca's COVID-19 shot
RE
01/14European Medicines Agency Asks AstraZeneca, Johnson & Johnson To Add Spinal Inflammatio..
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 079 M - -
Net income 2021 2 716 M - -
Net Debt 2021 24 814 M - -
P/E ratio 2021 54,7x
Yield 2021 2,35%
Capitalization 185 B 186 B -
EV / Sales 2021 5,83x
EV / Sales 2022 4,78x
Nbr of Employees 76 100
Free-Float -
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 119,68 $
Average target price 138,50 $
Spread / Average Target 15,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC-1.54%181 019
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317